Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Eltrombopag (Primary)
- Indications Immune thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms ESTIT
- 17 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 14 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Dec 2016.